Cutinases from Mycobacterium Tuberculosis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Inhibitory Effects of Plant Phenolic Compounds on Enzymatic and Cytotoxic Activities Induced by a Snake Venom Phospholipase A
295 VITAE, REVISTA DE LA FACULTAD DE QUÍMICA FARMACÉUTICA ISSN 0121-4004 / ISSNe 2145-2660. Volumen 18 número 3, año 2011. Universidad de Antioquia, Medellín, Colombia. págs. 295-304 INHIBITORY EFFECTS OF PLANT PHENOLIC COMPOUNDS ON ENZYMATIC AND CYTOTOXIC ACTIVITIES INDUCED BY A SNAKE VENOM PHOSPHOLIPASE A 2 EFECTOS INHIBITORIOS DE COMPUESTOS FENÓLICOS DE PLANTAS SOBRE LA ACTIVIDAD ENZIMÁTICA Y CITOTOXICA INDUCIDA POR UNA FOSFOLIPASA A 2 DE VENENO DE SERPIENTE Jaime A. PEREAÑEZ 1*, Vitelbina NÚÑEZ 1,2 , Arley C. PATIÑO 1, Mónica LONDOÑO 1, Juan C. QUINTANA 1 Received: 23 February 2010 Accepted: 25 April 2011 ABSTRACT Polyphenolic compounds have shown to inhibit toxic effects induced by snake venom proteins. In this work, we demonstrate that gallic acid, ferulic acid, caffeic acid, propylgallate and epigallocatechingallate inhibit the enzymatic activity of a phospholipase A 2 (PLA 2), using egg yolk as substrate. The IC50 values are between 0.38 – 3.93 mM. These polyphenolic compounds also inhibit the PLA 2 enzymatic activity when synthetic substrate is used. Furthermore, these compounds decreased the cyotoxic effect induced by a myotoxic PLA 2; specifically, epigallocatechin gallate exhibited the best inhibitory capacity with 90.92 ± 0.82%, while ferulic acid showed the lowest inhibitory activity with 30.96 ± 1.42%. Molecular docking studies were performed in order to determine the possible modes of action of phenolic compounds. All polyphenols showed hydrogen bonds with an active site of enzyme; moreover, epigallocatechingallate presented the strongest binding compared with the other compounds. Additionally, a preliminary structure-activity relationship analysis showed a correlation between the IC50 and the topological polar surface area of each compound (p = 0.0491, r = -0.8079 (-0.9878 to -0.2593)), which indicates the surface area required for each molecule to bind with the majority of the enzyme. -
Kramers' Theory and the Dependence of Enzyme Dynamics on Trehalose
catalysts Review Kramers’ Theory and the Dependence of Enzyme Dynamics on Trehalose-Mediated Viscosity José G. Sampedro 1,* , Miguel A. Rivera-Moran 1 and Salvador Uribe-Carvajal 2 1 Instituto de Física, Universidad Autónoma de San Luis Potosí, Manuel Nava 6, Zona Universitaria, San Luis Potosí C.P. 78290, Mexico; [email protected] 2 Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México C.P. 04510, Mexico; [email protected] * Correspondence: [email protected]fisica.uaslp.mx; Tel.: +52-(444)-8262-3200 (ext. 5715) Received: 29 April 2020; Accepted: 29 May 2020; Published: 11 June 2020 Abstract: The disaccharide trehalose is accumulated in the cytoplasm of some organisms in response to harsh environmental conditions. Trehalose biosynthesis and accumulation are important for the survival of such organisms by protecting the structure and function of proteins and membranes. Trehalose affects the dynamics of proteins and water molecules in the bulk and the protein hydration shell. Enzyme catalysis and other processes dependent on protein dynamics are affected by the viscosity generated by trehalose, as described by the Kramers’ theory of rate reactions. Enzyme/protein stabilization by trehalose against thermal inactivation/unfolding is also explained by the viscosity mediated hindering of the thermally generated structural dynamics, as described by Kramers’ theory. The analysis of the relationship of viscosity–protein dynamics, and its effects on enzyme/protein function and other processes (thermal inactivation and unfolding/folding), is the focus of the present work regarding the disaccharide trehalose as the viscosity generating solute. Finally, trehalose is widely used (alone or in combination with other compounds) in the stabilization of enzymes in the laboratory and in biotechnological applications; hence, considering the effect of viscosity on catalysis and stability of enzymes may help to improve the results of trehalose in its diverse uses/applications. -
Lipolytic Enzymes
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 3308-3312, April 1995 Biochemistry Interfacial activation-based molecular bioimprinting of lipolytic enzymes (lipases/phospholipase A2/nonaqueous media) ISMAEL MINGARRO, CONCEPCION ABAD, AND LORENZO BRACo* Departament de Bioquimica i Biologia Molecular, Facultat de Ciencies Biologiques, Universitat de Valencia, E-46100 Burjassot, Valencia, Spain Communicated by William P. Jencks, Brandeis University, Waltham, MA, October 19, 1995 (received for review June 28, 1994) ABSTRACT Interfacial activation-based molecular (bio)- ported yet, which contrasts with the extraordinary profusion imprinting (IAMI) has been developed to rationally improve during the last few years of nonaqueous studies of lipases. the performance of lipolytic enzymes in nonaqueous environ- Catalysis by lipolytic enzymes is characterized by the so-called ments. The strategy combinedly exploits (i) the known dra- interfacial activation (13), manifested as a pronounced activity matic enhancement of the protein conformational rigidity in increase upon substrate aggregation [i.e., over the substrate a water-restricted milieu and (ii) the reported conformational critical micelle concentration (cmc)]. It has long been pro- changes associated with the activation of these enzymes at posed that this activation should involve some discrete con- lipid-water interfaces, which basically involves an increased formational changes of the soluble enzyme in fixing itself at the substrate accessibility to the active site and/or an induction substrate surface (14). Recent evidence derived mainly from of a more competent catalytic machinery. Six model enzymes x-ray crystallographic studies in the case of triglyceride lipases have been assayed in several model reactions in nonaqueous (for review, see, for example, refs. -
Rnase 2 Sirna (H): Sc-92235
SANTA CRUZ BIOTECHNOLOGY, INC. RNase 2 siRNA (h): sc-92235 BACKGROUND PRODUCT RNase 2 [ribonuclease, RNase A family, 2 (liver, eosinophil-derived neuro- RNase 2 siRNA (h) is a pool of 2 target-specific 19-25 nt siRNAs designed toxin)], also known as non-secretory ribonuclease, EDN (eosinophil-derived to knock down gene expression. Each vial contains 3.3 nmol of lyophilized neurotoxin), RNase UpI-2 or RNS2, is a 161 amino acid protein that belongs siRNA, sufficient for a 10 µM solution once resuspended using protocol to the pancreatic ribonuclease family. Localizing to lysosome and cytoplasmic below. Suitable for 50-100 transfections. Also see RNase 2 shRNA granules, RNase 2 is expressed in leukocytes, liver, spleen, lung and body Plasmid (h): sc-92235-SH and RNase 2 shRNA (h) Lentiviral Particles: fluids. RNase 2 functions as a pyrimidine specific nuclease, and has a slight sc-92235-V as alternate gene silencing products. preference for uracil. RNase 2 is capable of various biological activities, For independent verification of RNase 2 (h) gene silencing results, we including mediation of chemotactic activity and endonucleolytic cleavage of also provide the individual siRNA duplex components. Each is available as nucleoside 3'-phosphates and 3'-phosphooligonucleotides. The gene encoding 3.3 nmol of lyophilized siRNA. These include: sc-92235A and sc-92235B. RNase 2 maps to human chromosome 14q11.2. STORAGE AND RESUSPENSION REFERENCES Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least 1. Yasuda, T., Sato, W., Mizuta, K. and Kishi, K. 1988. Genetic polymorphism one year from the date of shipment. -
Cutinase Structure, Function and Biocatalytic Applications
EJB Electronic Journal of Biotechnology ISSN: 0717-345 Vol.1 No.3, Issue of August 15, 1998. © 1998 by Universidad Católica de Valparaíso –- Chile Invited review paper/ Received 20 October, 1998. REVIEW ARTICLE Cutinase structure, function and biocatalytic applications Cristina M. L. Carvalho Centro de Engenharia Biológica e Química Instituto Superior Técnico 1000 Lisboa – Portugal Maria Raquel Aires-Barros Centro de Engenharia Biológica e Química Instituto Superior Técnico 1000 Lisboa – Portugal 1 Joaquim M. S. Cabral Centro de Engenharia Biológica e Química Instituto Superior Técnico 1000 Lisboa – Portugal Tel: + 351.1.8419065 Fax: + 351.1.8419062 E-mail: [email protected] http://www.ist.utl.pt/ This review analyses the role of cutinases in nature and Some microorganisms, including plant pathogens, have their potential biotechnological applications. The been shown to live on cutin as their sole carbon source cloning and expression of a fungal cutinase from (Purdy and Kolattukudy, 1975) and the production of Fusarium solani f. pisi, in Escherichia coli and extracellular cutinolytic enzymes has been presented (Purdy Saccharomyces cerevisiae hosts are described. The three and Kolattukudy, 1975; Lin and Kolattukudy, 1980). dimensional structure of this cutinase is also analysed Cutinases have been purified and characterized from and its function as a lipase discussed and compared with several different sources, mainly fungi (Purdy and other lipases. The biocatalytic applications of cutinase Kolattukudy, 1975 ; Lin and Kolattukudy, 1980; Petersen et are described taking into account the preparation of al., 1997; Dantzig et al., 1986; Murphy et al., 1996) and different cutinase forms and the media where the pollen (Petersen et al., 1997; Sebastian et al., 1987). -
GRAS Notice 653, Lysophospholipase from Aspergillus Nishimurae
GRAS Notice (GRN) No. 653 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm ORIGINAL SUBMISSION 000001 AB Enzymes GmbH – Feldbergstrasse 78 , D-64293 Darmstadt May 5, 2016 Office of Food Additive Safety (HFS-255), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Parkway, College Park, MD 20740. RE: GRAS NOTICE FOR lysophospholipase Enzyme Preparation From Trichoderma reesei Pursuant to proposed 21 C.F.R § 170.36, AB Enzymes GmbH is providing in electronic media format (determined to be free of computer viruses), based on scientific procedures – a generally recognized as safe (GRAS) notification for lysophospholipase enzyme preparation from Trichoderma reesei for use as a processing aid used in starch processing. The lysophospholipase enzyme preparation described herein when used as described above and in the attached GRAS notice is exempt from the premarket approval requirements applicable to food additives set forth in Section 409 of the Food, Drug, and Cosmetic Act and corresponding regulations. Please contact the undersigned by telephone or email if you have any questions or additional information is required. Candice Cryne Regulatory Affairs Manager 1 647-919-3964 [email protected] 000002 ~ AB Enzymes AB Enzymes GmbH - Feldbergstrasse 78, 0 -64293 Darmstadt ... AUf'~- 3 GR ·N000(,5 {~g~~~\§\Eli] May 5, 2016 Mfl.'< 21 201S Office of Food Additive Safety (HFS-255), OFFICE OF Center for Food Safety and Applied Nutrition, FOOD ADDITIVE SAFEi'f l Food and Drug Administration, L 5100 Paint Branch Parkway, College Park, MD 20740. RE: GRAS NOTICE FOR lysophospholipase Enzyme Preparation From Trichoderma reesei Pursuant to proposed 21 C.F.R § 170.36, AB Enzymes GmbH is providing in electronic media format (determined to be free of computer viruses), based on scientific procedures- a generally recognized as safe (GRAS) notification for lysophospholipase enzyme preparation from Trichoderma reesei for use as a processing aid used in starch processing . -
Purification and Characterization of Cutinase from Venturia Inaequalis
Physiology and Biochemistry Purification and Characterization of Cutinase from Venturia inaequalis Wolfram K611er and Diana M. Parker Assistant professor and research assistant, Department of Plant Pathology, Cornell University, New York State Agricultural Experiment Station, Geneva 14456. We thank Professor A. L. Jones for the isolates of Venturia inaequalis, Mr. Robert W. Ennis, Jr. for his help in cutin preparation, and Comstock Foods, Alton, NY, for the apple peels. Accepted for publication 16 August 1988. ABSTRACT K61ler, W., and Parker, D. M. 1989. Purification and characterization of cutinase from Venturia inaequalis. Phytopathology 79:278-283. Venturia inaequalis was grown in a culture medium containing purified cutinase from V. inaequalisis optimal at a pH of 6 and thus different from apple cutin as the sole carbon source. After 8 wk of growth an esterase was the alkaline pH-optimum reported for other purified cutinases. The isolated from the culture fluid and purified to apparent homogeneity. The hydrolysis of the model esterp-nitrophenyl butyrate was less affected by the enzyme hydrolyzed tritiated cutin and thus was identified as cutinase. The pH. The esterase activity was strongly inhibited by diisopropyl purified cutinase is a glycoprotein with a molecular mass of 21-23 kg/ mol, fluorophosphate, and the phosphorylation of one serine was sufficient for as determined by various procedures. Remarkable structural features are a complete inhibition. Thus, cutinase from V. inaequalis belongs to the class high content of glycine, a high content of nonpolar amino acids, two of serine hydrolases, a characterisitic shared with other fungal cutinases. disulfide bridges, and a high degree of hydrophobicity. -
Letters to Nature
letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997). -
Universal Riboclone™ Cdna Synthesis System
TECHNICAL MANUAL Universal RiboClone™ cDNA Synthesis System Instructions for Use of Product C4360 Revised 4/21 TM038 Universal RiboClone™ cDNA Synthesis System All technical literature is available at: www.promega.com/protocols/ Visit the web site to verify that you are using the most current version of this Technical Manual. E-mail Promega Technical Services if you have questions on use of this system: [email protected] 1. Description .........................................................................................................................................2 2. Product Components and Storage Conditions ........................................................................................3 3. General Considerations .......................................................................................................................4 3.A. Methods of cDNA Synthesis .........................................................................................................4 3.B. Choice of Primers .......................................................................................................................4 3.C. cDNA Cloning ............................................................................................................................4 3.D. Choice of Vector .........................................................................................................................8 3.E. RNA Preparation and Handling ...................................................................................................8 -
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z
REVIEW pubs.acs.org/CR The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z. Long* and Benjamin F. Cravatt* The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States CONTENTS 2.4. Other Phospholipases 6034 1. Introduction 6023 2.4.1. LIPG (Endothelial Lipase) 6034 2. Small-Molecule Hydrolases 6023 2.4.2. PLA1A (Phosphatidylserine-Specific 2.1. Intracellular Neutral Lipases 6023 PLA1) 6035 2.1.1. LIPE (Hormone-Sensitive Lipase) 6024 2.4.3. LIPH and LIPI (Phosphatidic Acid-Specific 2.1.2. PNPLA2 (Adipose Triglyceride Lipase) 6024 PLA1R and β) 6035 2.1.3. MGLL (Monoacylglycerol Lipase) 6025 2.4.4. PLB1 (Phospholipase B) 6035 2.1.4. DAGLA and DAGLB (Diacylglycerol Lipase 2.4.5. DDHD1 and DDHD2 (DDHD Domain R and β) 6026 Containing 1 and 2) 6035 2.1.5. CES3 (Carboxylesterase 3) 6026 2.4.6. ABHD4 (Alpha/Beta Hydrolase Domain 2.1.6. AADACL1 (Arylacetamide Deacetylase-like 1) 6026 Containing 4) 6036 2.1.7. ABHD6 (Alpha/Beta Hydrolase Domain 2.5. Small-Molecule Amidases 6036 Containing 6) 6027 2.5.1. FAAH and FAAH2 (Fatty Acid Amide 2.1.8. ABHD12 (Alpha/Beta Hydrolase Domain Hydrolase and FAAH2) 6036 Containing 12) 6027 2.5.2. AFMID (Arylformamidase) 6037 2.2. Extracellular Neutral Lipases 6027 2.6. Acyl-CoA Hydrolases 6037 2.2.1. PNLIP (Pancreatic Lipase) 6028 2.6.1. FASN (Fatty Acid Synthase) 6037 2.2.2. PNLIPRP1 and PNLIPR2 (Pancreatic 2.6.2. -
(10) Patent No.: US 8119385 B2
US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. -
SERUM PARAOXONASE ACTIVITY in RENAL TRANSPLANT RECIPIENTS Saritha Gadicherla1, Suma M
Jebmh.com Original Research Article SERUM PARAOXONASE ACTIVITY IN RENAL TRANSPLANT RECIPIENTS Saritha Gadicherla1, Suma M. N2, Parveen Doddamani3 1Associate Professor, Department of Biochemistry, Sambhram Institute of Medical Sciences and Research, KGF, Karnataka, India. 2Professor, Department of Biochemistry, JSS Medical College, Mysuru, Karnataka, India. 3Consultant Biochemist, Department of Clinical Biochemistry, JSS Hospital, Mysuru, Karnataka, India. ABSTRACT BACKGROUND Serum paraoxonase is an enzyme synthesised in the liver. It is known to prevent atherosclerosis by inhibiting oxidation of low- density lipoprotein. Renal transplant recipients have increased tendency for developing atherosclerosis and cardiovascular disease. Reduced activity of serum paraoxonase contributes to accelerated atherosclerosis and increased cardiovascular complications in these patients. The aim of this study was to estimate serum paraoxonase activity in renal transplant recipients and compare it with healthy controls. MATERIALS AND METHODS 30 renal transplant recipients and 30 age and sex matched healthy controls were taken for the study. Serum paraoxonase activity, blood urea, serum creatinine and uric acid were estimated in these groups. The serum paraoxonase activity was correlated with urea, creatinine and uric acid levels. RESULTS Serum paraoxonase activity was reduced in renal transplant recipients compared to healthy controls. There was a negative correlation between paraoxonase activity and the levels of urea, creatinine and uric acid levels. CONCLUSION In this study, the paraoxonase activity was reduced in renal transplant recipients compared to controls. The increased cardiovascular disease in these patients could be due to reduced paraoxonase activity. KEYWORDS Paraoxonase, Renal Transplant Recipients, Atherosclerosis, Oxidised Low-Density Lipoprotein. HOW TO CITE THIS ARTICLE: Gadicherla S, Suma MN, Doddamani P. Serum paraoxonase activity in renal transplant recipients.